Granite Point Capital Management’s TherapeuticsMD TXMD Stock Holding History

Granite Point Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-3,509	Closed	-$1.2M	–	96
2016 Q3	$1.2M	Sell	3,509 -390	-10%	-$142K	0.47%	38
2016 Q2	$1.66M	Buy	+3,899	New	+$1.61M	0.71%	22
2015 Q4	$519K	Buy	+1,000	New	+$369K	0.08%	63
2014 Q3	–	Sell	-2,400	Closed	-$530K	–	101
2014 Q2	$530K	Buy	2,400 +180	+8%	+$40.1K	0.36%	58
2014 Q1	$700K	Sell	2,220 -2,580	-54%	-$822K	0.5%	63
2013 Q4	$1.25M	Buy	+4,800	New	+$1.05M	0.21%	54

Other funds holding TXMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Granite Point Capital Management's TXMD Position: Q4 2016 in Review

Granite Point Capital Management sold out of TherapeuticsMD (TXMD) in Q4 2016, closing a stake of 3,509 shares — an estimated $1.2M sold.

Granite Point Capital Management first reported a position in TXMD in Q4 2013 and held it in 6 quarters. The position peaked at $1.66M in Q2 2016. 146 funds tracked by Wall St. Rank hold TXMD as of Q4 2016.

Granite Point Capital Management reported no remaining TherapeuticsMD position as of Q4 2016 after selling out during the quarter.
Granite Point Capital Management sold 3,509 TherapeuticsMD shares in Q4 2016, an estimated $1.2M.
Granite Point Capital Management first reported a position in TherapeuticsMD in Q4 2013 and held it in 6 quarters.
Granite Point Capital Management's TherapeuticsMD position peaked at $1.66M in Q2 2016.
146 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2016.

Based on Granite Point Capital Management's 13F filing for Q4 2016, filed 7 Feb 2017.